WilmerHale Guides Corvia Medical in $35M Strategic Investment by Edwards Lifesciences

WilmerHale Guides Corvia Medical in $35M Strategic Investment by Edwards Lifesciences

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, has entered into an agreement with Edwards Lifesciences. The agreement includes a $35 million investment and provides the exclusive option for Edwards to acquire the company at a later date. Funds will be used to complete the REDUCE LAP-HF II clinical trial of the InterAtrial Shunt Device (IASD®), the world's first transcatheter device for the treatment of heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF).

The WilmerHale team representing Corvia in this transaction was led by Jason Kropp and includes Bill Caporizzo, Belinda Juran, Scott Kilgore, Hal Leibowitz, Bruce Manheim, George Shuster, Kimberly Wethly, Andrew Langworthy, Alex Civetta, Byron Crowe, Todd Rosenthal and Ben Kelsey.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel